Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
about
Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@en
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@nl
type
label
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@en
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@nl
prefLabel
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@en
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@nl
P2093
P2860
P1476
Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.
@en
P2093
Feng-Mei Zhan
Hong-Fu Cai
Li-Zhu Weng
Mao-Bai Liu
Xiao-Feng Luo
P2860
P356
10.1007/S40261-017-0587-Z
P577
2017-10-13T00:00:00Z